Product Description
Pimavanserin (ACP-103) is a selective inverse agonist of the 5-hydroxytryptamine 2A (5-HT2A) receptor intended to treat patients with Parkinson's disease psychosis (PDP). (Sourced from: https://pubmed.ncbi.nlm.nih.gov/26744739/)
Mechanisms of Action: 5-HT2 Inverse Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Bangladesh | United States
Approved Indications: Parkinson Disease | Hallucinations | Schizophrenia
Known Adverse Events: Confusion | Edema
Company: Acadia
Company Location: SAN DIEGO CA 92130
Company CEO: Stephen R. Davis
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Argentina, Australia, Bulgaria, China, Colombia, Croatia, Czech Republic, France, Georgia, Hungary, India, Italy, Lithuania, Mexico, Poland, Romania, Russia, Serbia, South Africa, Spain, Ukraine, United States
Active Clinical Trial Count: 17
Highest Development Phases
Phase 3: Autism Spectrum Disorder|Other|Parkinson's Disease|Psychotic Disorders|Schizophrenia
Phase 2: Conduct Disorder
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| NCT05999240 | P2 |
Not yet recruiting |
Autism Spectrum Disorder |
2026-02-15 |
|
| 2023H0014 | P2 |
Recruiting |
Conduct Disorder |
2026-01-01 |
|
| ACP-103-070 | P2 |
Unknown Status |
Autism Spectrum Disorder |
2025-10-27 |
|
| ACP-103-070 | P3 |
Recruiting |
Autism Spectrum Disorder |
2025-07-01 |